LLY

992.23

+0.48%↑

JNJ

224.08

-0.79%↓

ABBV

205.44

-0.58%↓

UNH

367.84

+1.31%↑

AZN

185.21

+2.03%↑

LLY

992.23

+0.48%↑

JNJ

224.08

-0.79%↓

ABBV

205.44

-0.58%↓

UNH

367.84

+1.31%↑

AZN

185.21

+2.03%↑

LLY

992.23

+0.48%↑

JNJ

224.08

-0.79%↓

ABBV

205.44

-0.58%↓

UNH

367.84

+1.31%↑

AZN

185.21

+2.03%↑

LLY

992.23

+0.48%↑

JNJ

224.08

-0.79%↓

ABBV

205.44

-0.58%↓

UNH

367.84

+1.31%↑

AZN

185.21

+2.03%↑

LLY

992.23

+0.48%↑

JNJ

224.08

-0.79%↓

ABBV

205.44

-0.58%↓

UNH

367.84

+1.31%↑

AZN

185.21

+2.03%↑

Home・Aandelen Lijst・Ovid therapeutics Inc

Ovid therapeutics Inc

Open

SectorGezondheidszorg

2.76 -0.72

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.74

Max

2.94

Belangrijke statistieken
By Trading Economics
Inkomsten	22M 9.7M
Verkoop	586K 718K
Winstmarge	1,345.822
Werknemers	23
EBITDA	-152K -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+71.67% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	368M 507M
Vorige openingsprijs	3.48
Vorige sluitingsprijs	2.76

Nieuwssentiment

By Acuity

21%

79%

65 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.275 / 0.33 Steun & Weerstand

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mei 2026, 23:43 UTC

Belangrijke Nieuwsgebeurtenissen

New Zealand's Unemployment Rate Falls in 1Q

5 mei 2026, 23:20 UTC

Populaire aandelen

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mei 2026, 21:48 UTC

Winsten

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mei 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mei 2026, 00:00 UTC

Marktinformatie

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mei 2026, 23:39 UTC

Marktinformatie

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mei 2026, 22:26 UTC

Marktinformatie

AMD Data-Center Business Continues to Surge -- Market Talk

5 mei 2026, 22:20 UTC

Marktinformatie

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mei 2026, 22:08 UTC

Winsten

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mei 2026, 22:07 UTC

Winsten

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:48 UTC

Winsten

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mei 2026, 21:48 UTC

Winsten

Pan American Silver 1Q Rev $1.2B >PAAS

5 mei 2026, 21:42 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:38 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:30 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:29 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:26 UTC

Winsten

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mei 2026, 21:25 UTC

Winsten

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mei 2026, 21:25 UTC

Winsten

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mei 2026, 21:24 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:18 UTC

Winsten

Mistras Backs 2026 Rev $730M-$750M >MG

5 mei 2026, 21:17 UTC

Winsten

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mei 2026, 21:15 UTC

Winsten

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mei 2026, 21:12 UTC

Winsten

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mei 2026, 21:11 UTC

Winsten

SSR Mining 1Q Rev $581.8M >SSRM

5 mei 2026, 21:10 UTC

Winsten

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mei 2026, 21:10 UTC

Winsten

SSR Mining 1Q EPS $1.16 >SSRM

5 mei 2026, 21:08 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:01 UTC

Winsten

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mei 2026, 21:01 UTC

Populaire aandelen

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

71.67% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.03 USD 71.67%

Hoogste 7 USD

Laagste 4 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

65 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.